Xiaojin Wu1,2,3,4,5, Yiyu Xie1,2,3,4, Chang Wang6, Yue Han1,2,3,4, Xiebing Bao1,2,3,4, Shoubao Ma1,2,3,4, Ahmet Yilmaz5, Bingyu Yang1,2,3,4, Yuhan Ji1,2,3,4, Jinge Xu1,2,3,4, Hong Liu1,2,3,4, Suning Chen1,2,3,4, Jianying Zhang7, Jianhua Yu5,8, Depei Wu1,2,3,4. 1. Jiangsu Institute of Hematology, The First Affiliated Hospital of Soochow University, Suzhou, China. 2. Institute of Blood and Marrow Transplantation and. 3. Collaborative Innovation Center of Hematology, Soochow University, Suzhou, China. 4. Key Laboratory of Thrombosis and Hemostasis of Ministry of Health, Suzhou, China. 5. Comprehensive Cancer Center, The Ohio State University, Columbus, Ohio, USA. 6. School of Radiation Medicine and Protection, Medical College of Soochow University, Collaborative Innovation Center of Radiological Medicine of Jiangsu Higher Education Institutions, Jiangsu Provincial Key Laboratory of Radiation Medicine and Protection, Suzhou, China. 7. Center for Biostatistics and. 8. Division of Hematology, Department of Internal Medicine, The Ohio State University, Columbus, Ohio, USA.
Abstract
BACKGROUND: There are very few studies investigating metabolic biomarkers to predict acute graft-versus-host disease (aGVHD) after allogeneic hematopoietic stem cell transplantation (HSCT). Metabolic models can provide a framework for analyzing the information-rich omics data sets in this setting. METHODS: Four hundred and fifty-six samples from one hundred and fourteen consecutive patients who underwent HSCT from January 2012 to May 2014 were collected for this study. The changes in serum metabolite levels were investigated using a gas chromatography-mass spectrometry-based metabolomics approach and underwent statistical analysis. RESULTS: Significant metabolic changes were observed on day 7. The stearic acid/palmitic acid (SA/PA) ratio was effective in the diagnosis of grade II-IV aGVHD. Multivariate analysis showed that patients with high SA/PA ratios on day 7 after HSCT were less likely to develop II-IV aGVHD than patients with low SA/PA ratios (odds ratio [OR] = 0.06, 95% CI 0.02-0.18, P < 0.001). After the adjustment for clinical characteristics, the SA/PA ratio had no significant effect on overall survival (hazard ratio [HR] = 1.95, 95% CI 0.92-4.14, P = 0.08), and patients in the high SA/PA ratio group were significantly more likely to relapse than those in the low ratio group (HR = 2.26, 95% CI 1.04-4.91, P = 0.04). CONCLUSION: Our findings suggest that the SA/PA ratio on day 7 after HSCT is an excellent biomarker to predict both aGVHD and relapse. The serum SA/PA ratio measured on day 7 after transplantation may improve risk stratification for aGVHD and relapse after allogeneic stem cell transplantation. FUNDING: National Natural Science Foundation of China (81470346, 81773361), Priority Academic Program Development of Jiangsu Higher Education Institutions, Jiangsu Natural Science Foundation (BK20161204), Innovation Capability Development Project of Jiangsu Province (BM2015004), Jiangsu Medical Junior Talent Person award (QNRC2016707), and NIH (AI129582 and NS106170).
BACKGROUND: There are very few studies investigating metabolic biomarkers to predict acute graft-versus-host disease (aGVHD) after allogeneic hematopoietic stem cell transplantation (HSCT). Metabolic models can provide a framework for analyzing the information-rich omics data sets in this setting. METHODS: Four hundred and fifty-six samples from one hundred and fourteen consecutive patients who underwent HSCT from January 2012 to May 2014 were collected for this study. The changes in serum metabolite levels were investigated using a gas chromatography-mass spectrometry-based metabolomics approach and underwent statistical analysis. RESULTS: Significant metabolic changes were observed on day 7. The stearic acid/palmitic acid (SA/PA) ratio was effective in the diagnosis of grade II-IV aGVHD. Multivariate analysis showed that patients with high SA/PA ratios on day 7 after HSCT were less likely to develop II-IV aGVHD than patients with low SA/PA ratios (odds ratio [OR] = 0.06, 95% CI 0.02-0.18, P < 0.001). After the adjustment for clinical characteristics, the SA/PA ratio had no significant effect on overall survival (hazard ratio [HR] = 1.95, 95% CI 0.92-4.14, P = 0.08), and patients in the high SA/PA ratio group were significantly more likely to relapse than those in the low ratio group (HR = 2.26, 95% CI 1.04-4.91, P = 0.04). CONCLUSION: Our findings suggest that the SA/PA ratio on day 7 after HSCT is an excellent biomarker to predict both aGVHD and relapse. The serum SA/PA ratio measured on day 7 after transplantation may improve risk stratification for aGVHD and relapse after allogeneic stem cell transplantation. FUNDING: National Natural Science Foundation of China (81470346, 81773361), Priority Academic Program Development of Jiangsu Higher Education Institutions, Jiangsu Natural Science Foundation (BK20161204), Innovation Capability Development Project of Jiangsu Province (BM2015004), Jiangsu Medical Junior Talent Person award (QNRC2016707), and NIH (AI129582 and NS106170).
Authors: Barbara Büchel; Peter Rhyn; Stefan Schürch; Claudia Bühr; Ursula Amstutz; Carlo R Largiadèr Journal: Biomed Chromatogr Date: 2012-03-27 Impact factor: 1.902
Authors: Bin Xiao; Yu Wang; Wei Li; Megan Baker; Jian Guo; Kelly Corbet; Ephraim L Tsalik; Qi-Jing Li; Scott M Palmer; Christopher W Woods; Zhiguo Li; Nelson J Chao; You-Wen He Journal: Blood Date: 2013-09-16 Impact factor: 22.113
Authors: Cora Weigert; Katrin Brodbeck; Harald Staiger; Christiana Kausch; Fausto Machicao; Hans U Häring; Erwin D Schleicher Journal: J Biol Chem Date: 2004-03-17 Impact factor: 5.157
Authors: Ran Reshef; Wael Saber; Javier Bolaños-Meade; George Chen; Yi-Bin Chen; Vincent T Ho; Doris M Ponce; Ryotaro Nakamura; Michael J Martens; John A Hansen; John E Levine Journal: J Clin Oncol Date: 2021-01-28 Impact factor: 50.717
Authors: Fathima A Mohamed; Govindarajan Thangavelu; Stephanie Y Rhee; Peter T Sage; Roddy S O'Connor; Jeffrey C Rathmell; Bruce R Blazar Journal: Front Immunol Date: 2021-10-12 Impact factor: 8.786